Supplementary material 1: STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

<table>
<thead>
<tr>
<th>Section/Topic</th>
<th>Item #</th>
<th>Recommendation</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title and abstract</strong></td>
<td>1</td>
<td><em>(a)</em> Indicate the study’s design with a commonly used term in the title or the abstract</td>
<td>Page 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>(b)</em> Provide in the abstract an informative and balanced summary of what was done and what was found</td>
<td>Page 2</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td>2</td>
<td>Explain the scientific background and rationale for the investigation being reported</td>
<td>Page 3-4</td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td>3</td>
<td>State specific objectives, including any prespecified hypotheses</td>
<td>Page 3-4</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design</td>
<td>4</td>
<td>Present key elements of study design early in the paper</td>
<td>Methods</td>
</tr>
<tr>
<td>Setting</td>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</td>
<td>Methods</td>
</tr>
<tr>
<td>Participants</td>
<td>6</td>
<td><em>(a)</em> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</td>
<td>Methods</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>(b)</em> For matched studies, give matching criteria and number of exposed and unexposed</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Variables</td>
<td>7</td>
<td>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</td>
<td>Methods</td>
</tr>
<tr>
<td>Data sources/</td>
<td>8*</td>
<td>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</td>
<td>Methods</td>
</tr>
<tr>
<td>measurement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bias</td>
<td>9</td>
<td>Describe any efforts to address potential sources of bias</td>
<td>Statistical Analyses</td>
</tr>
<tr>
<td>Study size</td>
<td>10</td>
<td>Explain how the study size was arrived at</td>
<td>Statistical Analyses</td>
</tr>
<tr>
<td>Quantitative variables</td>
<td>11</td>
<td>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</td>
<td>Statistical Analyses</td>
</tr>
<tr>
<td>Statistical methods</td>
<td>12</td>
<td><em>(a)</em> Describe all statistical methods, including those used to control for confounding</td>
<td>Statistical Analyses</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>(b)</em> Describe any methods used to examine subgroups and interactions</td>
<td>Statistical Analyses</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>(c)</em> Explain how missing data were addressed</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
(d) If applicable, explain how loss to follow-up was addressed
Not applicable

(e) Describe any sensitivity analyses
Statistical Analyses

**Results**

Participants 13*
(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
S2

(b) Give reasons for non-participation at each stage
S2

(c) Consider use of a flow diagram
S2

Descriptive data 14*
(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
Results; Tables 1 and 2

(b) Indicate number of participants with missing data for each variable of interest
Results

(c) Summarise follow-up time (eg, average and total amount)
Results

Outcome data 15*
Report numbers of outcome events or summary measures over time
Results

Main results 16
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
Results; Tables 3 and 4

(b) Report category boundaries when continuous variables were categorized
Results; Tables 3 and 4

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Not applicable

Other analyses 17
Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Results; Figure 1

**Discussion**

Key results 18
Summarise key results with reference to study objectives
Discussion - Summary of main findings

**Limitations**

Interpretation 20
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Discussion

Generalisability 21
Discuss the generalisability (external validity) of the study results
Discussion

**Other information**

Funding 22
Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
Page 12
Supplementary material 2. Derivation of the analytic sample

N=8,592
PREVEND participants eligible for blood sample measures

N=1,150
No information on components of FLI and HSI and CVD risk markers

N=7,442
Participants with baseline information on components of FLI and HSI and relevant CVD risk markers

N=1,102
Excluded on the basis of
(i) Prevalent history of CVD (n=390)
(ii) Prevalent renal disease (n=14)
(iii) Prevalent liver disease (n=27)
(iv) Prevalent malignancy (n=121)
(v) Excessive alcohol use (n=377)
(vi) Lipid medication (n=173)

N=6,340
Participants included in the analysis of FLI, HSI and CVD risk

CVD, cardiovascular disease; FLI, fatty liver index; HIS, hepatic steatosis index